Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03605862 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection
A Phase 3 study, sponsored by Romark Laboratories L.C..
- Completed
- Registry status
- Phase 3
- Development phase
- 1,756
- Enrollment target
NCT03605862: Completed Phase 3 study, sponsored by Romark Laboratories L.C..
NCT03605862 is a Phase 3 study that has completed, run by Romark Laboratories L.C.. The registered enrollment target is 1,756 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (127% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03605862, a Phase 3 study, has completed, sponsored by Romark Laboratories L.C..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,756 participants
- Enrollment target
Study Summary
Trial to evaluate efficacy and safety of nitazoxanide in the treatment of colds due to Enterovirus/Rhinovirus infection
Primary Outcome
Subjects used the FLU-PRO questionnaire once daily in the evening to score the severity of 32 FLU-PRO symptoms. Symptom response was deemed achieved when the rating for each of the 32 FLU-PRO symptoms was ≤ its assigned threshold for 2 consecutive daily diary periods without use of symptom relief medication. The symptom response thresholds were developed by applying an algorithm to blinded symptoms data to select the set of 32 symptom thresholds most closely associated with patient-reported usua
Interventions
- DRUG Placebo
- DRUG Nitazoxanide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,756 participants |
| Start Date | 2018-09-11 |
| Est. Completion | 2019-02-04 |
| Phase | Phase 3 |
What the finished NCT03605862 record still lists
NCT03605862 is an interventional study that assigns participants to a tested intervention. Its 1,756 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (127% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03605862 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03605862 about?
NCT03605862 is a clinical study titled "Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection". Trial to evaluate efficacy and safety of nitazoxanide in the treatment of colds due to Enterovirus/Rhinovirus infection
What is the current status of trial NCT03605862?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,756 participants. The study started on 2018-09-11. Estimated completion is 2019-02-04.
What interventions are being tested in trial NCT03605862?
The interventions under investigation include: Placebo (DRUG), Nitazoxanide (DRUG).
Who is sponsoring clinical trial NCT03605862?
This trial is sponsored by Romark Laboratories L.C., which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03605862's enrollment target sits among peer trials
1,756 128th of 2000 higher than 1,873 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06872892 · 1,755 participants · Phase 3
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
- NCT07062172 · 1,753 participants · NA
Lung Cancer Screening of Family Members of Patients With Mutation-Driven Lung Cancer
- NCT05934487 · 1,750 participants · NA
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
- NCT06954337 · 1,750 participants · NA
MATCH-UP: MAking Telehealth-Delivery of Cancer Care at Home Effective and Safe-Upscaled: A Pragmatic Cluster Randomized Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI